Temple Spinoff Express Cells Secures First Patent for Gene-Editing Technology
A three-year-old Philadelphia genetic engineering company spun out of Temple University has secured its first patent for its core gene-editing technology.
ExpressCells was awarded the U.S. patent for its “Fast-HDR” gene editing technology, developed to create advanced cell lines for drug discovery.
The inventor on the technology covered by the patent is Dr. Oscar Perez Leal, an assistant professor at the Temple University School of Pharmacy and a co-founder ExpressCells. He is also a scientific advisor to the company.
In 2019, ExpressCells raised $800,000 through a Series A financing round led by the Rowan Innovation Venture Fund and Keiretsu Forum Mid-Atlantic. The company, which has grown to eight employees, has raised a total of $1.75 million from private investors, according to Handel.
Read the full article here.